ProQR Therapeutics N.V (PRQR) concluded trading on Thursday at a closing price of $1.14, with 0.46 million shares of worth about $0.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -37.02% during that period and on April 17, 2025 the price remained unchanged. Currently the company’s common shares owned by public are about 102.71M shares, out of which, 70.76M shares are available for trading.
Stock saw a price change of 0.88% in past 5 days and over the past one month there was a price change of -30.06%. Year-to-date (YTD), PRQR shares are showing a performance of -56.98% which decreased to -43.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.07 but also hit the highest price of $4.62 during that period. The average intraday trading volume for ProQR Therapeutics N.V shares is 504.43K. The stock is currently trading -12.64% below its 20-day simple moving average (SMA20), while that difference is down -36.57% for SMA50 and it goes to -50.96% lower than SMA200.
ProQR Therapeutics N.V (NASDAQ: PRQR) currently have 102.71M outstanding shares and institutions hold larger chunk of about 42.77% of that.
The stock has a current market capitalization of $119.94M and its 3Y-monthly beta is at 0.46. It has posted earnings per share of -$0.35 in the same period. It has Quick Ratio of 3.95 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRQR, volatility over the week remained 9.52% while standing at 9.15% over the month.
Stock’s fiscal year EPS is expected to drop by -18.55% while it is estimated to decrease by -15.33% in next year. EPS is likely to shrink at an annualized rate of -15.79% for next 5-years, compared to annual growth of 25.70% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 10, 2025 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Oppenheimer stated ProQR Therapeutics N.V (PRQR) stock as an Outperform in their note to investors on January 10, 2025, suggesting a price target of $15 for the stock. On October 29, 2024, Raymond James Upgrade their recommendations, while on November 08, 2023, Chardan Capital Markets Upgrade their ratings for the stock with a price target of $2. Stock get a Mkt outperform rating from JMP Securities on March 30, 2023.
